Aurinia Pharmaceuticals Inc. (AUPH) Bundle
Understanding Aurinia Pharmaceuticals Inc. (AUPH) Revenue Streams
Understanding Aurinia Pharmaceuticals Inc. Revenue Streams
Primary Revenue Sources:
- Product Revenue: For the three months ended September 30, 2024, net product revenue was $55.5 million, compared to $40.8 million for the same period in 2023. For the nine months ended September 30, 2024, net product revenue reached $158.6 million, up from $116.2 million in 2023.
- License, Collaboration, and Royalty Revenue: For the three months ended September 30, 2024, this revenue was $12.3 million, down from $13.7 million in 2023. For the nine months, it was $16.7 million in 2024 compared to $14.2 million in 2023.
Year-over-Year Revenue Growth Rate:
- Three Months: The total net revenue for the three months ended September 30, 2024, was $67.8 million, a 24.3% increase from $54.5 million in 2023.
- Nine Months: Total net revenue for the nine months ended September 30, 2024, was $175.3 million, reflecting a 34.4% increase from $130.4 million in 2023.
Contribution of Different Business Segments to Overall Revenue:
| Segment | Q3 2024 Revenue | Q3 2023 Revenue | 9M 2024 Revenue | 9M 2023 Revenue |
|---|---|---|---|---|
| Product Revenue | $55.5 million | $40.8 million | $158.6 million | $116.2 million |
| License, Collaboration, and Royalty Revenue | $12.3 million | $13.7 million | $16.7 million | $14.2 million |
| Total Revenue | $67.8 million | $54.5 million | $175.3 million | $130.4 million |
Analysis of Significant Changes in Revenue Streams:
- Increased product revenue primarily resulted from enhanced sales of LUPKYNIS, attributed to deeper market penetration, with approximately 2,422 patients on therapy as of September 30, 2024, compared to 1,939 patients a year prior.
- The decrease in license, collaboration, and royalty revenue in Q3 2024 was influenced by the recognition of a $10 million milestone in Q3 2023 for pricing and reimbursement approval in Europe, which did not recur in the same quarter of 2024.
Percentage Contribution to Total Revenue:
| Period | Specialty Pharmacies | Collaboration Partnership |
|---|---|---|
| Q3 2024 | 81% | 16% |
| Q3 2023 | 77% | 21% |
| 9M 2024 | 87% | 11% |
| 9M 2023 | 90% | 9% |
A Deep Dive into Aurinia Pharmaceuticals Inc. (AUPH) Profitability
A Deep Dive into Aurinia Pharmaceuticals Inc. Profitability
Gross Profit Margin: For the three months ended September 30, 2024, the gross margin was approximately 91%, compared to 88% for the same period in 2023. For the nine months ended September 30, 2024, the gross margin was about 87%, down from 93% in 2023.
Operating Profit: The income from operations for the three months ended September 30, 2024, was $11.7 million compared to a loss of ($16.3 million) in the same period of 2023. For the nine months ended September 30, 2024, the loss from operations was ($3.0 million), an improvement from ($62.0 million) in 2023.
Net Profit: The net income for the three months ended September 30, 2024, was $14.4 million, compared to a net loss of ($13.4 million) for the same period in 2023. For the nine months ended September 30, 2024, the net income was $4.3 million, a significant recovery from a net loss of ($51.1 million) in 2023.
Trends in Profitability Over Time
The profitability trends show a marked improvement in 2024. The most notable changes include:
- Gross profit margins increasing in Q3 2024.
- A significant turnaround in operating income from a loss in 2023 to a profit in 2024.
- Net income moving from losses in 2023 to profitability in 2024.
Comparison of Profitability Ratios with Industry Averages
When compared to industry averages, the profitability metrics as of Q3 2024 are as follows:
| Metric | Aurinia Pharmaceuticals | Industry Average |
|---|---|---|
| Gross Profit Margin | 91% | 80% |
| Operating Profit Margin | 17.3% | 10% |
| Net Profit Margin | 21.2% | 5% |
Analysis of Operational Efficiency
Operational efficiency has improved significantly with reduced costs and better revenue management. Key insights include:
- Cost of sales decreased to $6.0 million from $6.8 million year-over-year for Q3 2024.
- SG&A expenses decreased to $42.4 million in Q3 2024 from $47.8 million in Q3 2023.
- Research and development expenses fell to $3.0 million in Q3 2024 from $13.6 million in Q3 2023.
Overall, the operational efficiency metrics indicate a strong focus on cost management, contributing to improved profitability margins.
Debt vs. Equity: How Aurinia Pharmaceuticals Inc. (AUPH) Finances Its Growth
Debt vs. Equity: How Aurinia Pharmaceuticals Inc. Finances Its Growth
As of September 30, 2024, the company had total liabilities of $161.4 million compared to $170.1 million at December 31, 2023. This includes both current and non-current liabilities.
The breakdown of current liabilities includes:
- Accounts payable and accrued liabilities: $56.8 million
- Deferred revenue: $4.3 million
- Other current liabilities: $1.6 million
- Finance lease liabilities: $14.9 million
- Operating lease liabilities: $1.0 million
Total current liabilities amounted to $78.6 million as of September 30, 2024.
The company also has long-term liabilities consisting mainly of finance lease liabilities, which totaled $66.0 million as of September 30, 2024.
The debt-to-equity ratio is a key indicator of financial health. As of September 30, 2024, the debt-to-equity ratio stood at 0.42, calculated as:
| Total Debt | Total Shareholders' Equity | Debt-to-Equity Ratio |
|---|---|---|
| $161.4 million | $388.0 million | 0.42 |
This ratio is below the industry average of 0.5, indicating a lower reliance on debt financing compared to peers.
In terms of recent debt activity, the company initiated a finance lease for its manufacturing facility in June 2023, which has contributed to the interest expense of $3.7 million for the nine months ended September 30, 2024, compared to $1.5 million for the same period in 2023.
As of September 30, 2024, the company had cash, cash equivalents, and investments totaling $348.7 million, providing a robust liquidity position to manage its debt obligations and operational needs.
The balance between debt and equity financing is evident as the company has pursued a share repurchase program, repurchasing approximately 3.4 million shares for $18.6 million as of September 30, 2024. This program aims to enhance shareholder value while managing the capital structure effectively.
Overall, Aurinia's financial strategy reflects a cautious approach to leverage, maintaining a healthy balance sheet while funding its growth initiatives through a mix of debt and equity.
Assessing Aurinia Pharmaceuticals Inc. (AUPH) Liquidity
Assessing Aurinia Pharmaceuticals Inc.'s Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as follows:
Current Assets: $440.5 million
Current Liabilities: $78.6 million
Current Ratio = Current Assets / Current Liabilities = 5.61
Quick Ratio: The quick ratio, which excludes inventories from current assets, is calculated as:
Quick Assets (Current Assets - Inventories): $440.5 million - $38.7 million = $401.8 million
Quick Ratio = Quick Assets / Current Liabilities = 5.11
Analysis of Working Capital Trends
As of September 30, 2024, working capital stands at:
Working Capital = Current Assets - Current Liabilities = $440.5 million - $78.6 million = $361.9 million
This shows an increase from the previous year, where working capital was $347.6 million as of December 31, 2023.
Cash Flow Statements Overview
Cash flow trends for the nine months ended September 30, 2024, are summarized below:
| Cash Flow Type | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash provided by operating activities | $14,274 | ($47,773) |
| Net cash used in investing activities | $39 | ($449) |
| Net cash used in financing activities | ($26,046) | $447 |
| Net decrease in cash and cash equivalents | ($11,733) | ($47,775) |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, cash, cash equivalents, and restricted cash total approximately $37.1 million, while investments are valued at $311.6 million. This liquidity position provides sufficient coverage for operational expenses, including commercialization activities for LUPKYNIS and other commitments.
Accounts receivable as of September 30, 2024, amount to $36.5 million, an increase from $24.1 million at December 31, 2023. This indicates improved cash collection processes and effective sales growth, which contributes positively to liquidity.
Moreover, the company has no credit loss allowance recorded due to the nature of its investments, indicating a stable outlook for cash flows.
Is Aurinia Pharmaceuticals Inc. (AUPH) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the price-to-earnings (P/E) ratio for the company is 58.0, calculated using the net income of $14.35 million and the diluted earnings per share of $0.10. The price-to-book (P/B) ratio stands at 3.1, based on total shareholders’ equity of $388.0 million and common shares outstanding of 143.1 million.
The enterprise value-to-EBITDA (EV/EBITDA) ratio is calculated using the enterprise value of approximately $550.0 million and EBITDA of $11.7 million, resulting in an EV/EBITDA of 47.0.
| Valuation Metric | Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | 58.0 |
| Price-to-Book (P/B) Ratio | 3.1 |
| Enterprise Value-to-EBITDA (EV/EBITDA) | 47.0 |
Over the last 12 months, the stock price has experienced fluctuations, starting at approximately $6.50 and reaching a high of $9.00 before settling at around $5.77. The average trading volume has been 1.2 million shares per day, with significant trading activity noted following quarterly earnings releases.
Currently, the company does not offer a dividend, as indicated by a dividend yield of 0%. The payout ratio is also not applicable given the absence of dividends.
Analyst consensus on the stock valuation is mixed, with recommendations categorized as follows:
- Buy: 5 analysts
- Hold: 3 analysts
- Sell: 1 analyst
The average target price set by analysts is $7.50, suggesting a potential upside from the current trading price.
Key Risks Facing Aurinia Pharmaceuticals Inc. (AUPH)
Key Risks Facing Aurinia Pharmaceuticals Inc.
Aurinia Pharmaceuticals Inc. is exposed to a variety of internal and external risks that can significantly impact its financial health. Key risk factors include industry competition, regulatory changes, and market conditions.
1. Industry Competition
The pharmaceutical industry is highly competitive, with numerous companies vying for market share in the treatment of lupus nephritis and related conditions. As of September 30, 2024, the company reported a net product revenue of $55.5 million for the third quarter, up from $40.8 million in the same period in 2023. This growth is primarily due to increased sales of its product, LUPKYNIS, but competition remains fierce, particularly from established players in the market.
2. Regulatory Changes
Regulatory scrutiny is a constant concern in the pharmaceutical sector. The company is heavily reliant on the approval and ongoing support of its products by regulatory bodies such as the FDA. As of September 30, 2024, the company had cash, cash equivalents, and restricted cash totaling $37.1 million, which is critical for funding regulatory compliance and post-approval commitments for LUPKYNIS.
3. Market Conditions
Market conditions can greatly affect sales and revenue. For instance, the total net revenue was $67.8 million for the three months ended September 30, 2024, compared to $54.5 million in 2023. However, this revenue is sensitive to changes in market demand and pricing pressures.
4. Operational Risks
Operational risks include disruptions in the supply chain or manufacturing processes, which can lead to delays in product availability. For the nine months ended September 30, 2024, the company reported a total cost of sales of $22.7 million, reflecting the costs associated with manufacturing and distributing its products.
5. Financial Risks
Financial risks are also notable. The company reported an interest expense of $1.2 million for the third quarter of 2024. Additionally, the total liabilities stood at $161.4 million as of September 30, 2024, which could impact the company’s financial flexibility and ability to invest in growth opportunities.
6. Strategic Risks
Strategic risks may arise from the company’s focus on a limited number of products. As of September 30, 2024, approximately 81% of total net revenues were derived from two main specialty pharmacies. This high dependency on a few customers poses a risk if any of these relationships were to deteriorate.
7. Mitigation Strategies
The company has implemented various strategies to mitigate these risks, including diversifying its product offerings and strengthening partnerships with key stakeholders. The restructuring expenses were approximately $7.8 million for the nine months ended September 30, 2024, aimed at optimizing operations and reducing costs.
| Risk Factor | Description | Impact | Mitigation Strategy |
|---|---|---|---|
| Industry Competition | Numerous competitors in the lupus nephritis market. | Pressure on pricing and market share. | Diversification of product portfolio. |
| Regulatory Changes | Dependence on FDA approvals. | Potential for delays and increased costs. | Investment in compliance and regulatory affairs. |
| Market Conditions | Fluctuations in market demand. | Impact on revenue stability. | Market analysis and adaptive pricing strategies. |
| Operational Risks | Supply chain disruptions. | Delays in product availability. | Strengthening supplier relationships. |
| Financial Risks | High level of liabilities. | Reduced financial flexibility. | Cost management and efficiency improvements. |
| Strategic Risks | Heavy reliance on a few customers. | Vulnerability to customer attrition. | Diverse customer acquisition strategies. |
Future Growth Prospects for Aurinia Pharmaceuticals Inc. (AUPH)
Future Growth Prospects for Aurinia Pharmaceuticals Inc.
Key Growth Drivers
- Product Innovations: The primary driver for future growth is the continued commercialization of LUPKYNIS, a treatment for lupus nephritis (LN). The product revenue for the three months ended September 30, 2024, reached $55.5 million, compared to $40.8 million for the same period in 2023, reflecting increased market penetration.
- Market Expansions: The company has expanded its reach into new markets, including Japan, where LUPKYNIS received approval from the Ministry of Health, Labour, and Welfare. This approval resulted in a $10.0 million milestone revenue recognized in Q3 2024.
- Acquisitions: Strategic partnerships and collaborations, particularly with Otsuka, enhance growth potential through shared resources and market access.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, total net revenue was $175.3 million, up from $130.4 million in 2023, indicating a growth of approximately 34.4% year-over-year. Analysts project continued revenue growth driven by rising demand for LUPKYNIS and potential new product launches.
Strategic Initiatives or Partnerships
The collaboration with Otsuka is vital for future growth, involving both product sales and royalty revenues. As of September 30, 2024, the collaboration accounted for 16% of total net revenues. The agreement includes tiered royalties on net sales, which can range from 10% to 20%.
Competitive Advantages
Aurinia's competitive edge lies in its strong intellectual property portfolio and established relationships with specialty pharmacies. The company currently derives 81% of its revenue from two main specialty pharmacies in the U.S.. Additionally, the recent increase in patient therapy adherence, with a 12-month persistency rate rising to 57% as of September 30, 2024, supports a robust customer base.
| Metric | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Total Revenue | $67.8 million | $54.5 million | +24.5% |
| Net Product Revenue | $55.5 million | $40.8 million | +36.3% |
| License, Collaboration, and Royalty Revenue | $12.3 million | $13.7 million | -10.2% |
| Gross Margin | 91% | 88% | +3% |
As of September 30, 2024, the company maintains a healthy cash position, with cash, cash equivalents, and investments totaling $348.7 million. This liquidity supports ongoing commercialization efforts and strategic initiatives aimed at enhancing growth potential.
Aurinia Pharmaceuticals Inc. (AUPH) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Aurinia Pharmaceuticals Inc. (AUPH) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Aurinia Pharmaceuticals Inc. (AUPH)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Aurinia Pharmaceuticals Inc. (AUPH)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.